In this podcast, Dr. Matthew Silva, Executive Vice President, Scientific Applications, Invicro along with Dr. Gregory Goldmacher, Executive Director, Translational Biomarkers and Head of Clinical Imaging, Merck Research Labs discuss innovations in IO imaging.
Together, Dr. Silva and Dr. Goldmacher address:
- The evolution of treatment response criteria in immuno-oncology
- Novel Tracers: Monitoring tumor or immune cell populations with imaging
- Radiomics, AI and Digital Biomarkers
Matthew Silva, Ph.D., brings 16 years of diverse imaging experience from pharmaceutical and contract research organizations including 4 previous years at Invicro during which he helped build out the Boston lab. Most recently he was Senior Director of Translational Biology at Vertex Pharmaceuticals, where he ran the in vivo imaging and histopathology groups. Previously, Matt led imaging groups at Amgen, Millennium and Takeda Pharmaceuticals, during which he supported broad use of imaging biomarkers to support drug discovery and development. He holds a PhD and Masters in Biomedical Engineering from Worcester Polytechnic Institute. In his role as EVP of Scientific Applications, he will work across discovery, translational, and clinical projects providing scientific expertise with a focus outside of neuroscience and will assist in strengthening relationships in the pharmaceutical industry.